

Prof. Dr. rer. nat. Holger Kalthoff

Present position:	retired (since 10/2015) <u>Guest professor, University Hospital Zhejiang University, Hangzhou, China</u>
Former position:	Professor (C3) Division of Molecular Oncology Inst. for Experimental Cancer Research (Deputy Director)
Inst. for Experimental Cancer Research	Tel.: +49 (0) 431-500 - 30520 Fax: +49 (0) 431-500 - 30503
UKSH Campus Kiel Arnold-Heller-Str. 3 (building 18) D-24105 Kiel, Germany	h.kalthoff@email.uni-kiel.de http://www.iet.uni-kiel.de

1. Scientific Career:

1970	Commenced study of biology at the University of Hamburg, FRG
1976	Awarded degree in microbiology (grade "1")
1982	Awarded PhD in cell biology (grade "1") from the Dept. of Cell Biology at the University Clinic Hamburg
1978 -1981	Research assistant: Dept. of Cell Biology, University of Hamburg
1982 -1984	Post doctoral fellow, Dept. of Clinical Immunology, University Clinic Hamburg
1983, 85, 87	International short-term research stays at the Wistar-Institute, Philadelphia, NIH, Bethesda and Georgetown University, Washington, DC
1985 -1993	Head of an Independent Research Group (funded by the German Federal Ministry of Science & Technology), University Clinic Hamburg
since 1993	Assistant professor ("Habilitation" in immunology & cell biology)
since 1993	Appointment as Head of Molecular Oncology Lab at the Clinic for General Surgery, University Hospital Kiel
since 1998	Appointment as Professor for Molecular Oncology, University of Kiel, Germany
1998 -2010	Member of the managing board of the „SFB-415“
2002- 2008	Vice director of the Clinic for General Surgery and Thoracic Surgery
since 2004	Director of Division of Molecular Oncology
2005 -2011	Member of the Steering Committee of I@I Excellence Cluster Initiative in S-H
2008-2015	Scientific Director -interim- of the Comprehensive Cancer Center North & Deputy Director of the newly founded Institute for Experimental Cancer Research
2010-2015	Member of the Managing Board of Directors, MOIN-CC (Molecular Imaging North- Competence Center)

2. Awards and fellowships:

- 1979: Research fellowship (EMBO): University of Leiden, NL
- 1988: "Martini-Prize", Hamburg
- 1988: "Konjetzny-Prize", Hamburg
- 1998: Endowed professorship of the "Deutsche Krebshilfe" (German Cancer Aid)

3. Research focus:

- Non-canonical signaling and resistance mechanisms of death receptors
- Microenvironment and pancreatic cancer
- Clinically adapted murine tumor models & Molecular imaging
- Anti-inflammatory therapy concepts for pancreatic cancer
- Detection and characterization of circulating tumor cells / biomarkers in GI cancers

4. Memberships, Reviewer Activities and Editorial Board Memberships

- Deutsche Gesellschaft für Immunologie
- Deutsche Gesellschaft für Zellbiologie
- Schleswig-Holsteinische Krebsgesellschaft e.V.
- Deutsche Krebsgesellschaft
- Deutsche Gesellschaft für Chirurgie
- American Association for Cancer Research

- DFG, BMBF, EU, Sander-Stiftung, Deutsche Krebshilfe, B.- I. Fond, Humboldt-Foundation, and many others

- Br J Cancer, Cancer Res, Clin. Cancer Res, Int J Cancer, Gastroenterology, GUT, MCB, Oncogene, and many others

- Langenbecks Archives of Surgery; Hepatobiliary & Pancreatic Diseases Int.

5. Education, teaching and training

- Member of the "Fachausschuss der DKH für die Nachwuchsförderung"

- Numerous (>>100) doctoral, diploma, master thesis projects in medical and life science

- Habilitation projects (> 10) in medical and life science

- Responsible for Molecular Oncology module in the Medical Life Science curriculum, CAU, Kiel

- Scientific Advisor for "Exzellenz Akademie der Deutschen Gesellschaft für Chirurgie"

- Member (second) of Faculty for Mathematics and Natural Sciences

- 20 years of education and training of Chinese guest scientists (Hangzhou, PR China)

Research grants (since 2002)

- DFG: SFB415/ A3
07/2004-06/2007 337,000 €
- DFG: SFB415/ A3
07/2007-06/2010 399,900 €
- DFG: Peer-reviewed funding within the Excellence Cluster
“Inflammation at Interfaces”
(3 projects: miniproposal, animal model, graduate fellowship) 170,000 €
- DFG: KA1346/2-1
03/2009-02/2012 (E 13 ½ + E 8 + Sachmittel 93,500 €)
- DFG: EG318/2-1: „Pankreas-Tumor-Konsortium Kiel“ (joint project J.E & H.K.)
09/2010-09/2013 (1x E13½, 1x E6 + Sachmittel 94,037 €)
- DFG: TR1063/3-1:“SKELMET TP4“ (joint project A.T. & H. K.)
07/2011-07/2014 369,350 €
- Deutsche Krebshilfe: German Pancreatic Cancer Net, PaCa
06/2002-03/2006 319,000 €
- Deutsche Krebshilfe: (joint project D.Adam, Immunology & H.K.)
“TRAIL-induced necroptosis” 02/2012-02/2015 302,854 €
- NGFNplus: Integrated genomic investigation of CRC (TP1)
2008-2010 146,600 €
- BMBF-MoBiMed: „TOMCAT“
08/2008-12/2011 486,899 €
- BMBF-0315812G: “Algae Against Cancer” (AAC)
07/2010-06/2013 145,862 €
- Ministry for Economy and Science, S-H: MOIN S-H*
03/2005-02/2008 238,000 €
- Ministry for Economy and Science, S-H: MOIN CC*
04/2009-12/2013, Project 1 361,000 €
- Ministry for Economy and Science, S-H: MOIN CC*
2012-12/2013, Project 4 130,000 €
- EU Project: Marie Curie Initial Training Network: “IonTraC”
01/2012-09/2015, Project 9 224,444 €
Ion Transport Proteins in Control of Cancer Cell Behaviour

DFG Funding in “Excellence Cluster Inflammation at Interfaces”
“ Exosomal biomarker in sera of patients with IBD and -associated diseases”
01/2014 - 12/2016 (subproject Q TP2) 25,000 €

Damp-Stiftungsprofessur (endowed professorship)
“Translational Nanomedicine” 462,000 €

Total: > 4,300,000 €

Industry-sponsored grants (since 2000)

- | | |
|--|------------|
| • Merck-Darmstadt | 100,000 €* |
| • Conbio- GmbH, Kiel
(*jointly with the Inst. of Pathology) | 160,000 €* |
| • Apogenix GmbH, Heidelberg | 54,000 € |
| • Metanomics, Berlin | 5,000 € |

Total: 31,000 €

Patents

Herstellung und Verwendung antitumoraler Cyclodepsipeptide;
DE 10 2008 005 097 A1; Offenlegung: 23.07.2009
(Imhoff J. et. al)

Molekulare Bildgebung von Tumoren mit Nah-Infrarot-fluoreszierenden Konjugaten des
Chemokins CXCL12=SDF-1
Erfindungsmeldung am 02.11.2009
(Mentlein R. et. al)

Means and Methods for diagnosing pancreatic cancer in a subject
EP 10164624.8 und US 61/350042 (metanomics health GmbH, Mayerle, J, Greifswald,
Kalthoff, H.)

Researcher ID Key figures (2016) for Holger Kalthoff, PhD

Total articles in publication list 253 (248 with citation)

Sum of times cited 8204


Average citations per article 33.08

h-Index 50

This graph shows the number of times the articles on the publication list have been cited in each of the last 20 years.

Note: Only articles from Web of Science Core Collection with citation data are included in the calculations. [More information about these data.](#)

Citation Distribution by year



Publications since 2010

2010

Lemke J, Noack A, Adam D, Tchikov V, Bertsch U, Röder C, Schütze S, Wajant H, **Kalthoff H**, Trauzold A. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. *Journal of Molecular Medicine* 2010 88(7):729-40.

Ehrenschwender M, Siegmund D, Wicovsky A, Kracht M, Dittrich-Breiholz O, Spindler V, Waschke J, **Kalthoff H**, Trauzold A, Wajant H. Mutant PIK3CA licenses TRAIL and CD95L to induce non-apoptotic caspase-8-mediated ROCK activation. *Cell Death and Differentiation* 2010 17(9):1435-47.

Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T, **Kalthoff H**, Trauzold A, Seher A, Henkler F, Kneitz C, Wajant H. Soluble and transmembrane tumor necrosis factor-like weak inducer of apoptosis (TWEAK) differentially activate the classical and noncanonical NF κ B pathway. *J Immunology* 2010 185(3): 1593-605.

Bauerschlag D, Schem C, Tiwari S, Egberts J, Weigel M, **Kalthoff H**, Jonat W, Maass N, Meinhold-Heerlein I. Sunitinib (SU11248) Inhibits Growth of Human Ovarian Cancer in Xenografted Mice. *Anticancer Res* 2010 30(9):3355-60.

Rückert F, Dawelbait G, Winter C, Hartmann A, Denz A, Ammerpohl O, Schroeder M, Schackert H, Sipos B, Klöppel G, **Kalthoff H**, Saeger H, Pilarsky C, Grützmann R. Examination of Apoptosis Signaling in Pancreatic Cancer by Computational Signal Transduction Analysis. *PLoS One* 2010 5(8):e12243.

2011

von Forstner C, Zuhayra M, Ammerpohl O, Zhao Y, Tiwari S, Jansen O, **Kalthoff H**, Henze E, Egberts JH. Expression of LAT1 and analysis of Iodine-123-Methyltyrosine tumor uptake in a pancreatic xenotransplantation model using fused High-Resolution-Micro-SPECT-MRI. *HBPD Int* 2011 10(1):30-37.

Kürbitz C, Heise D, Redmer T, Goumas F, Arlt A, Lemke J, Rimbach G, **Kalthoff H**, Trauzold A. Epicatechin gallate and catechin gallate are superior to epigallocatechin gallate in growth suppression and anti-inflammatory activities in pancreatic tumor cells. *Cancer Science* 2011 120(4):728-734.

Castro FA, Försti A, Buch S, **Kalthoff H**, Krauss C, Bauer M, Egberts J, Schiewind B, Bröring CD, Schreiber S, Schmitt M, Hampe J, Hemminki K, Schafmeyer C. TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. *Eur. J Cancer* 2011 47(8):1203-10.

Meincke M, Tiwari S., Kattermann K., **Kalthoff H**, Mentlein R. Near-infrared molecular imaging of tumors via chemokine receptors CXCR4 and CXCR7 *Clin Exp Metastasis* 2011 28(8): 713-20.

Tiwari S., Egberts JH, Korniienko O., Köhler L., Trauzold A., Glüer CC, **Kalthoff H**. Assessment of anti-inflammatory tumor treatment efficacy by longitudinal monitoring employing sonographic micro morphology in a preclinical mouse model. *BMC Medical Imaging* 2011 Jun 23;11:15.

2012

Sperveslage J., Frank S., Heneweer C., Egberts J., Schniewind B., Buchholz M., Bergmann F., Giese N., Munding J., Hahn S., **Kalthoff H.**, Klöppel G., Sipos B. Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma. *Int. J. Cancer* 2012 Aug 15;131(4):E371-381.

Tiwari S, Schem C, Lorenzen AC, Kayser O, Wiese C, Graeff C, Peña J, Marshall RP, Heller M, **Kalthoff H**, Jonat W, Glüer CC Application of ex vivo micro-computed tomography for assessment of in vivo fluorescence and plain radiographic imaging for monitoring bone metastases and osteolytic lesions *J Bone Miner Metab* 2012 May;30(3):373-380.

Ammerpohl O., Pratschke J., Schafmeyer C., Haake A., Faber W., v. Kampen O., Brosch M., Sipos B., v. Schönfels W., Balschun K., Röcken C., Arlt A., Schniewind B., Grauholm J., **Kalthoff H.**, Neuhaus P., Stickel F., Schreiber S., Becker T., Siebert R., Hampe J. Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma. *Int. J. Cancer* 2012 130(6):1319-28.

Schäfer H, Geismann C, Heneweer C, Egberts JH, Korniienko O, Kiefel H, Moldenhauer G, Bachem MG, **Kalthoff H**, Altevogt P, Sebens S. Myofibroblast-induced tumorigenicity of pancreatic ductal epithelial cells is L1CAM-dependent *Carcinogenesis* 2012 33(1): 84-93.

Naumann CM, Sperveslage JD, Hamann MF, Leuschner I, Emme D, Weder L, Al-Najar AA, Lemke J, Sipos B, Jünemann KP, **Kalthoff H**. Establishment and Characterization of Primary Cell lines of Squamous Cell Carcinoma of the Penis and its Metastases. *J Urol* 2012 Jun;187(6):2236-2242.

Hinz S, Bockhorst J, Röder C, Egberts JH, Schafmeyer C, Küchler T, Becker T, **Kalthoff H**. Disseminated tumor cells in the bone marrow negatively influence survival after resection of colorectal liver metastases. *Ann Surg Oncol* 2012 Aug;19(8):2539-2546.

Lascorz J, Bevier M, Schönfels WV, **Kalthoff H**, Aselmann H, Beckmann J, Egberts J, Buch S, Becker T, Schreiber S, Hampe J, Hemminki K, Försti A, Schafmeyer C. Polymorphisms in the mitochondrial oxidative phosphorylation chain genes as prognostic markers for colorectal cancer. *BMC Med Genet*. 2012 Apr 30;13(1):31.

Winterhoff BJ, Arlt A, Duttmann A, Ungefroren H, Schäfer H, **Kalthoff H**, Kruse ML. Characterisation of FAP-1 expression and CD95 mediated apoptosis in the A818-6 pancreatic adenocarcinoma differentiation system. *Differentiation* 2012 Mar;83(3):148-157.

Lascano V, Zabalegui LF, Cameron K, Guadagnoli M, Jansen M, Burggraaf M, Versloot M, Rodermond H, van der Loos C, Carvalho-Pinto CE, **Kalthoff H**, Medema JP, Hahne M. The TNF family member APRIL promotes colorectal tumorigenesis. *Cell Death Differ*. 2012 Nov; 19(11):1826-1835.

Schulz D, Nachtigall J, Geisen U, **Kalthoff H**, Imhoff JF, Fiedler HP, Süssmuth RD. Silvalactam, a 24-membered macrolactam antibiotic produced by *Streptomyces* sp. Tü 6392*. *J Antibiot (Tokyo)* 2012 Jul;65(7): 369-372.

2013

von Kampen O, Buch S, Nothnagel M, Azocar L, Molina H, Brosch M, Erhart W, von Schönfels W, Egberts J, Seeger M, Arlt A, Balschun T, Franke A, Lerch MM, Mayerle J, Kratzer W, Boehm BO, Huse K, Schniewind B, Tiemann K, Jiang ZY, Han TQ, Mittal B, Srivastava A, Fenger M, Jørgensen T, Schirin-Sokhan R, Tönjes A, Wittenburg H, Stumvoll M, **Kalthoff H**, Lammert F, Tepel J, Puschel K, Becker T, Schreiber S, Platzner M, Völzke H, Krawczak M, Miquel JF, Schafmayer C, Hampe J. Genetic and functional identification of the likely causative variant for cholesterol gallstone disease at the ABCG5/8 lithogenic locus.

Hepatology. 2013 Jun;57(6):2407-17

Zhou DH, Yang LN, Röder C, **Kalthoff H**, Trauzold A. TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells. *Hepatobiliary Pancreat Dis Int* 2013 Feb 15;12(1)94-98.

Schem C, Bauerschlag D, Bender S, Lorenzen AC, Loermann D, Hamann S, Rösel F, **Kalthoff H**, Glüer CC, Jonat W, Tiwari S. Preclinical evaluation of Sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases. *BMC Cancer* 2013 Jan 24;13:32.

Lascorz J, Bevier M, V Schönfels W, **Kalthoff H**, Aselmann H, Beckmann J, Egberts J, Buch S, Becker T, Schreiber S, Hampe J, Hemminki K, Schafmayer C, Försti A. Association study identifying polymorphisms in CD47 and other extracellular matrix pathway genes as putative prognostic markers for colorectal cancer. *Int J Colorectal Dis*. 2013 Feb 28;(2):173-181.

Böger C, **Kalthoff H**, Goodman SL, Röcken C. Validation and Comparison of Anti-av β 3 and Anti-av β 5 Rabbit Monoclonal Versus Murine Monoclonal Antibodies in Four Different Tumor Entities. *Appl Immunohistochem Mol Morphol* 2013 Dec;21(6):553-60.

Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Fürst D, Mytilineos J, **Kalthoff H**, Janssen O, Oberg HH, Kabelitz D. Shedding of endogenous MHC class I-related chain molecules A and B (MICA and MICB) from different human tumor entities: Heterogeneous involvement of the disintegrin and metalloproteases 10 and 17 (ADAM10 and ADAM17). *Int J Cancer*. 2013 Oct 1;133(7):1557-66

Eisenach PA, Soeth E, Röder C, Klöppel G, Tepel J, **Kalthoff H**, Sipos B. Dipeptidase 1 (DPEP1) is a marker for the transition from low-grade to high-grade intraepithelial neoplasia and an adverse prognostic factor in colorectal cancer. *Br J Cancer* 2013 Aug 6;109(3):694-703.

Lehnen NC, von Mässenhausen A, **Kalthoff H**, Zhou H, Glowka T, Schütte U, Höller T, Riesner K, Boehm D, Merkelbach-Bruse S, Kirfel J, Perner S, Gütgemann I. Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. *Histopathology* 2013 Aug; 63(2):157-166.

2014

Böger C, **Kalthoff H**, Goodman SL, Behrens HM, Röcken C. Integrins and their ligands are expressed in non-small cell lung cancer but not correlated with parameters of disease progression. *Virchows Arch* 2014 Jan;464(1):69-78

Haselmann V, Kurz A, Bertsch U, Hübner S, Olempska-Müller M, Fritsch J, Häsler R, Pickl A, Fritsche H, Annewanter F, Engler C, Fleig B, Bernt A, Röder C, Schmidt H, Gelhaus C, Hauser C, Egberts JH, Heneweer C, Rohde AM, Böger C, Knippschild U, Röcken C, Adam D, Walczak H, Schütze S, Janssen O, Wulczyn FG, Wajant H, **Kalthoff H**, Trauzold A. Nuclear Death Receptor TRAILR2 Inhibits Maturation of Let-7 and Promotes Proliferation of Pancreatic and Other Tumor cells. *Gastroenterology* 2014 Jan;146(1):278-290.

Unruh D, Turner K, Srinivasan R, Kocatürk B, Qi X, Chu Z, Aronow BJ, Plas DR, Gallo CA, **Kalthoff H**, Kirchofer D, Ruf W, Ahmad SA, Lucas FV, Versteeg HH, Bogdanov VY. Alternatively Spliced Tissue Factor Contributes to Tumor Spread and Activation of Coagulation in Pancreatic Ductal Adenocarcinoma. *Int J Cancer*. 2014 Jan 1;134(1):9-20

Voigt S, Philipp S, Davarnia P, Winoto-Morbach S, Röder C, Arenz C, Trauzold A, Kabelitz D, Schütze S, **Kalthoff H**, Adam D. TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells. *BMC Cancer* 2014 Feb 7;14(1):74

Helm O, Mennrich R, Petrick D, Goebel L, Freitag-Wolf S, Röder C, **Kalthoff H**, Röcken C, Sipos B, Kabelitz D, Schäfer H, Oberg HH, Wesch D, Sebens S. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma. *PLoS One* 2014 9(5):e94357

Madhavan B, Yue S, Galli U, Rana S, Gross W, Müller M, Giese NA, **Kalthoff H**, Becker T, Büchler MW, Zöller M. Combined Evaluation of a Panel of Protein and miRNA Serum Exosome Biomarkers for Pancreatic Cancer Diagnosis Increases Sensitivity and Specificity. *Int J Cancer* 2014 Nov 12. doi: 10.1002/ijc.29324.

Böger C, Warneke VS, Behrens HM, **Kalthoff H**, Goodman SL, Becker T, Röcken C. Integrins $\alpha(v)\beta(3)$ and $\alpha(v)\beta(5)$ as prognostic, diagnostic, and therapeutic targets in gastric cancer. *Gastric Cancer*. 2014 Oct 15. Epub ahead of print.

2015

Lascano V, Hahne M, Papon L, Cameron K, Roeder C, Schafmayer C, Driessen L, van Eenennaam H, **Kalthoff H**, Medema JP. Circulating APRIL levels are correlated with advanced disease and prognosis in rectal cancer patients. *Oncogenesis*. 2015 Jan 26;4:e136. doi: 10.1038

Goumas F, Holmer R, Egberts J, Gontarewicz A, Heneweer C, Geisen U, Hauser C, Mende MM, Legler K, Röcken C, Becker T, Waetzig G, Rose-John S, **Kalthoff H**. Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrences in orthotopic xenograft models of pancreatic cancer. *Int J Cancer* 2015, epub ahead of print.

von Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J, Legler K, Annewanter F, Campbell A, Taraborrelli L, Grosse-Wilde A, Coy JF, El-Bahrawy M, Bergmann F, Koschny R, Werner J, Ganten T, Schweiger T, Hoetzenecker K, Kenessey I, Hegedüs B, Bergmann M, Hauser C, Egberts J, Becker T, Röcken C, **Kalthoff H**, Trauzold A, Anderson K, Sansom O, Walczak H. Cancer-cell autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion and metastasis. *CANCER CELL* doi: 10.1016/j.ccell.2015.02.014

Cardone RA, Greco MR, Zeeberg K, Zaccagnino A, Saccomano M, Bellizzi A, Bruns P, Menga M, Pilarsky C, Schwab A, Alves F, **Kalthoff H**, Vasavola V, Reshkin SJ. A Novel NHE1-Entered Signaling Cassette Drives Epidermal Growth Factor Receptor-Dependent Pancreatic Tumor Metastasis and Is a Target for Combination Therapy. *Neoplasia* 2015; 17(2), 155-166.

Hinz S, Tepel J, Röder C, **Kalthoff H**, Becker T. Profile of Serum Factors and Disseminated Tumor Cells Before and After Radiofrequency Ablation Compared to Resection of Colorectal Liver Metastases – A Pilot Study. *Anticancer Res* 35: Accepted Feb 2015

Fritsche H, Heilmann T, Tower RJ, Hauser C, von Au A, El-Sheikh D, Campbell GM, Alp G, Schewe D, Hübner S, Tiwari S, Kownatzki D, Boretius S, Adam D, Jionat W, Becker T, Glüer CC, Zöller M, **Kalthoff H**, Schem C, Trauzold A. TRAIL-R2 promotes skeletal metastasis in a breast cancer xenograft mouse model. *Oncotarget*, 2015, epub ahead of print.

Cytokeratin 20 positive circulating tumor cells are a marker for response after neoadjuvant chemoradiation but not for prognosis in patients with rectal cancer.
Hinz S, Röder C, Tepel J, Hendricks A, Schafmayer C, Becker T, **Kalthoff H**. *BMC Cancer*. 2015 Dec 16;15:953. doi: 10.1186/s12885-015-1989-z. PMID: 26674974

Molecular Mechanisms by Which a Fucus vesiculosus Extract Mediates Cell Cycle Inhibition and Cell Death in Pancreatic Cancer Cells.
Geisen U, Zenthoefer M, Peipp M, Kerber J, Plenge J, Managò A, Fuhrmann M, Geyer R, Hennig S, Adam D, Piker L, Rimbach G, **Kalthoff H**. *Mar Drugs*. 2015 Jul 20;13(7):4470-91. doi: 10.3390/md13074470. PMID: 26204945

Profile of serum factors and disseminated tumor cells before and after radiofrequency ablation compared to resection of colorectal liver metastases - a pilot study.
Hinz S, Tepel J, Röder C, **Kalthoff H**, Becker T. *Anticancer Res*. 2015 May;35(5):2961-7. PMID: 25964582

Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis.
Philipp S, Sosna J, Plenge J, **Kalthoff H**, Adam D. *Cell Commun Signal*. 2015 Apr 29;13:25. doi: 10.1186/s12964-015-0103-0. PMID: 25925126

[Interleukin-6 trans-signaling increases the expression of carcinoembryonic antigen-related cell adhesion molecules 5 and 6 in colorectal cancer cells.](#)

Holmer R, Wätzig GH, Tiwari S, Rose-John S, **Kalthoff H**.

BMC Cancer. 2015 Dec 16;15:975. doi: 10.1186/s12885-015-1950-1.

PMID: 26673628

2016

[Concentration of circulating miRNA-containing particles in serum enhances miRNA detection and reflects CRC tissue-related deregulations.](#)

ElSharawy A, Röder C, Becker T, Habermann JK, Schreiber S, Rosenstiel P,

Kalthoff H.

Oncotarget. 2016 Sep 23. doi: 10.18632/oncotarget.12205. [Epub ahead of print]

PMID: 27683108

[In silico analysis of the transportome in human pancreatic ductal adenocarcinoma.](#)

Zaccagnino A, Pilarsky C, Tawfik D, Sebens S, Trauzold A, Novak I, Schwab A,

Kalthoff H.

Eur Biophys J. 2016 Sep 21. [Epub ahead of print]

PMID: 27652669

[Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma.](#)

Zaccagnino A, Managò A, Leanza L, Gontarewitz A, Linder B, Azzolini M, Biasutto L, Zoratti M, Peruzzo R, Legler K, Trauzold A, **Kalthoff H**, Szabo I.

Oncotarget. 2016 Aug 16. doi: 10.18632/oncotarget.11299. [Epub ahead of print]

PMID: 27542263

[Differences and Similarities in TRAIL- and Tumor Necrosis Factor-Mediated Necroptotic Signaling in Cancer Cells.](#)

Sosna J, Philipp S, Fuchslocher Chico J, Saggau C, Fritsch J, Föll A, Plenge J, Arenz C, Pinkert T, **Kalthoff H**, Trauzold A, Schmitz I, Schütze S, Adam D.

Mol Cell Biol. 2016 Sep 26;36(20):2626-44. doi: 10.1128/MCB.00941-15. Print 2016 Oct 15.

[Negative control of TRAIL-R1 signaling by transforming growth factor \$\beta\$ 1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.](#)

Radke DI, Ungefroren H, Helm O, Voigt S, Alp G, Braun H, Hübner S, Dilchert J, Sebens S, Adam D, **Kalthoff H**, Trauzold A.

Cell Signal. 2016 Nov;28(11):1652-62. doi: 10.1016/j.cellsig.2016.07.016. Epub 2016 Aug 1.

PMID: 27492861

[Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts.](#)

Heits N, Heinze T, Bernsmeier A, Kerber J, Hauser C, Becker T, **Kalthoff H**, Egberts JH, Braun F.

BMC Cancer. 2016 May 20;16:322. doi: 10.1186/s12885-016-2360-8.

PMID: 27206490

[PD-L1 is an independent prognostic predictor in gastric cancer of Western patients.](#)

Böger C, Behrens HM, Mathiak M, Krüger S, **Kalthoff H**, Röcken C.
Oncotarget. 2016 Apr 26;7(17):24269-83. doi: 10.18632/oncotarget.8169.
PMID: 27009855

Increased survival rate by local release of diclofenac in a murine model of recurrent oral carcinoma.

Will OM, Purcz N, Chalaris A, Heneweer C, Boretius S, Purcz L, Nikkola L, Ashammakhi N, **Kalthoff H**, Glüer CC, Wiltfang J, Açil Y, Tiwari S.
Int J Nanomedicine. 2016 Oct 12;11:5311-5321. eCollection 2016

2017

Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations.

Böger C, Krüger S, Behrens HM, Bock S, Haag J, **Kalthoff H**, Röcken C.
Ann Oncol. 2017 Feb 9. doi: 10.1093/annonc/mdx047. [Epub ahead of print] No abstract available. PMID: 28184407

The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma.

Ling Q, Xu X, Ye P, Xie H, Gao F, Hu Q, Liu Z, Wei X, Röder C, Trauzold A, **Kalthoff H**, Zheng S.
Oncotarget. 2017 Jan 20. doi: 10.18632/oncotarget.14768. [Epub ahead of print] PMID: 28122349

Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.

Mayerle J, **Kalthoff H**, Reszka R, Kamlage B, Peter E, Schniewind B, González Maldonado S, Pilarsky C, Heidecke CD, Schatz P, Distler M, Scheiber JA, Mahajan UM, Weiss FU, Grützmann R, Lerch MM.
Gut. 2017 Jan 20. pii: gutjnl-2016-312432. doi: 10.1136/gutjnl-2016-312432. [Epub ahead of print] PMID: 28108468

Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients - a prospective study.

Hinz S, Hendricks A, Wittig A, Schafmayer C, Tepel J, **Kalthoff H**, Becker T, Röder C.
BMC Cancer. 2017 Jan 13;17(1):53. doi: 10.1186/s12885-016-3035-1.
PMID: 28086834

Ion channels in control of pancreatic stellate cell migration.

Storck H, Hild B, Schimmelpfennig S, Sargin S, Nielsen N, Zaccagnino A, Budde T, Novak I, **Kalthoff H**, Schwab A.
Oncotarget. 2017 Jan 3;8(1):769-784. doi: 10.18632/oncotarget.13647.

E2F1 Signalling is Predictive of Chemoresistance and Lymphogenic Metastasis in Penile Cancer: A Pilot Functional Study Reveals New Prognostic Biomarkers. Fenner F, Goody D, Protzel C, Erbersdobler A, Richter C, Hartz JM, Naumann CM, **Kalthoff H**, Herchenröder O, Hakenberg OW, Pützer BM. *Eur Urol Focus*. 2017 Mar 1. pii: S2405-4569(17)30056-1. doi: 10.1016/j.euf.2017.02.009. [Epub ahead of print]

Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo.

Leanza L, Romio M, Becker KA, Azzolini M, Trentin L, Managò A, Venturini E, Zaccagnino A, Mattarei A, Carraretto L, Urbani A, Kadow S, Biasutto L, Martini V, Severin F, Peruzzo R, Trimarco V, Egberts JH, Hauser C, Visentin A, Semenzato G, **Kalthoff H**, Zoratti M, Gulbins E, Paradisi C, Szabo I. *Cancer Cell*. 2017 Apr 10;31(4):516-531.e10. doi: 10.1016/j.ccell.2017.03.003.

REVIEWS since 2010

Ammerpohl O, Tiwari S, **Kalthoff H**. Target gene discovery for novel therapeutic agents in cancer treatment. *Methods Mol Biol*. 2010;576:427-45

Sebens S., **Kalthoff H**. Emerging therapeutic targets and agents for pancreatic cancer therapy – Where are we and where we have to go? *Anti Canc Agents Med Chem* 2011 Jun 1;11(5):408-10.

Röder C, Trauzold A, **Kalthoff H**. Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma. *E J Cell Biol* 2011 90(6-7):450-5.

Ling Q, Xu X, Zheng S, **Kalthoff H**. The diversity between pancreatic head and body/tail cancers: clinical parameters and in vitro models. *Hepatob Pancreat Dis*, 2013 Oct;12(5):480-487.

Holmer R, Goumas FA, Waetzig GH, Rose-John S, **Kalthoff H**. Interleukin-6: a villain in the drama of pancreatic cancer development and progression. *Hepatobiliary Pancreat Dis Int*. 2014 Aug;13(4):371-380.

Bertsch U, Röder C, **Kalthoff H**, Trauzold A. Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2. *Cell Death Dis*. 2014 Aug 28;5:e1390

[Target Gene Discovery for Novel Therapeutic Agents in Cancer Treatment.](#)

Tiwari S, Ammerpohl O, **Kalthoff H**.

Methods Mol Biol. 2016;1381:181-200. doi: 10.1007/978-1-4939-3204-7_10.

PMID: 26667461